E-LIB Suche - Ergebnisse für: Botton, Stéphane de

1

Final phase I substudy results of ivosidenib in patients wi..:

DiNardo, Courtney D. D ; Roboz, Gail J. ; Watts, Justin M...
Blood Advances. , 2024

Link: https://doi.org/10.1182/..

2

Differentiation syndrome associated with treatment with IDH..:

Montesinos, Pau ; Fathi, Amir T. ; de Botton, Stéphane...
Blood Advances. 8 (2024) 10 - p. 2509-2519 , 2024

Link: https://doi.org/10.1182/..

3

Somatic gene mutation patterns and burden influence outcome..:

Risueño, Alberto ; See, Wendy L. ; Bluemmert, Iryna...
Leukemia Research. 140 (2024) - p. 107497 , 2024

Link: https://doi.org/10.1016/..

4

P724: UPDATED SUBSTUDY RESULTS FOR IVOSIDENIB IN IDH1-MUTAN..:

Dinardo, Courtney ; Roboz, Gail ; M. Watts, Justin...
HemaSphere. 7 (2023) S3 - p. e75740ab , 2023

Link: https://doi.org/10.1097/..

5

P494: A FIRST-IN-HUMAN STUDY OF CD123 NK CELL ENGAGER SAR44..:

Selwyn Stein, Anthony ; Jongen-Lavrencic, Mojca ; Garciaz, Sylvain...
HemaSphere. 7 (2023) S3 - p. e66387cd , 2023

Link: https://doi.org/10.1097/..

6

MDS-457 Ivosidenib in Mutant IDH1 Relapsed/Refractory Myelo..:

DiNardo, Courtney D. ; Roboz, Gail J. ; Watts, Justin M....
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S366-S367 , 2023

Link: https://doi.org/10.1016/..

7

PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND..:

Botton, Stéphane de ; Cluzeau, Thomas ; Vigil, Carlos...
HemaSphere. 7 (2023) S3 - p. e50253dc , 2023

Link: https://doi.org/10.1097/..

8

When monoclonal gammopathy‐associated chronic neutrophilic ..:

Willekens, Christophe ; Chahine, Claude ; Dragani, Matteo...
eJHaem. 4 (2023) 3 - p. 823-826 , 2023

Link: https://doi.org/10.1002/..

9

POSTER: MDS-457 Ivosidenib in Mutant IDH1 Relapsed/Refracto..:

DiNardo, Courtney D. ; Roboz, Gail J. ; Watts, Justin M....
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S182 , 2023

Link: https://doi.org/10.1016/..

10

Enasidenib treatment in two individuals with D-2-hydroxyglu..:

Geoerger, Birgit ; Schiff, Manuel ; Penard-Lacronique, Virginie...
Nature Medicine. 29 (2023) 6 - p. 1358-1363 , 2023

Link: https://doi.org/10.1038/..

11

AML-469 Ivosidenib + Azacitidine vs Placebo + Azacitidine i..:

de Botton, Stéphane ; Montesinos, Pau ; Polo, Susana Vives...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S304 , 2023

Link: https://doi.org/10.1016/..

12

Targeting RARA overexpression with tamibarotene, a potent a..:

de Botton, Stéphane ; Cluzeau, Thomas ; Vigil, Carlos...
Blood Advances. 7 (2023) 9 - p. 1858-1870 , 2023

Link: https://doi.org/10.1182/..

13

Safety, efficacy, and PK/PD of vorasidenib in previously tr..:

DiNardo, Courtney D. ; De Botton, Stéphane ; Pollyea, Daniel A....
American Journal of Hematology. 98 (2023) 9 - p. , 2023

Link: https://doi.org/10.1002/..

14

POSTER: AML-469 Ivosidenib + Azacitidine vs Placebo + Azaci..:

de Botton, Stéphane ; Montesinos, Pau ; Polo, Susana Vives...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S166 , 2023

Link: https://doi.org/10.1016/..

15

Use of tamibarotene, a potent and selective RARα agonist, i..:

Stein, Eytan M. ; de Botton, Stephane ; Cluzeau, Thomas...
Leukemia & Lymphoma. 64 (2023) 12 - p. 1992-2001 , 2023

Link: https://doi.org/10.1080/..